Hutch News

Recent Stories

Still here

Tacoma’s ‘Art AIDS America’ exhibit carries a message that HIV researchers, activists support

Oct. 12, 2015 | By Mary Engel / Fred Hutch News Service

"Still Life with Forget-Me-Nots and One Week's Dose of Truvada" by Joey Terrill

Joey Terrill, "Still Life with Forget-Me-Nots and One Week's Dose of Truvada," 2012. Mixed media on canvas, 36-by-48 inches.

Joey Terrill / courtesy of Leslie-Lohman Museum of Gay and Lesbian Art

Rock Hushka came of age as an artist under the shadow of AIDS.

He was a high school student in North Dakota in 1983 when he first read in Time or Newsweek about what was then called the gay plague. It was barely two years after the first cases had been reported, when the number of known infections stood at a few thousand. Even with no idea how bad things would get, Hushka remembers thinking, “This is not OK.”

In the increasingly not-OK decade that followed, Hushka studied art at the University of Washington and the University of Wisconsin and was riveted by the “passionate and focused” response of artists to the crisis. Directly addressing the stigma surrounding AIDS, they demanded that attention be paid. “They showed that art can be an agent of change,” he said.

Today the Tacoma Art Museum’s chief curator, Hushka has brought together an exhibition that both examines and continues that tradition. The 127 works in Art AIDS America walk a younger generation through the 34-year history of HIV/AIDS as depicted by photographers Robert Mapplethorpe and Annie Leibovitz, graffiti-inspired artist Keith Haring, painter Jasper Johns, conceptual artist Barbara Kruger, performance artist Karen Findley and a host of equally powerful but less familiar names. At the same time, the exhibit reminds an AIDS-fatigued nation that, with 1.2 million Americans living with HIV and 50,000 new infections a year in the U.S., the battle isn’t over.

HIV researchers and activists say that the show, which opened last weekend and will run through Jan. 10, is exactly the medicine that’s needed for the global pandemic’s forgotten home front.

“HIV/AIDS is still a major health issue even if it’s not on the front pages of the newspapers every day,” said Dr. Jeffrey Schouten, director of the Office of HIV/AIDS Network Coordination, or HANC, which is based at Fred Hutchinson Cancer Research Center and works with prevention and treatment networks across the nation. “Art plays a unique role in highlighting some of the social issues below the radar screen of people who think AIDS is over.” 

Continue reading >

Q&A: Dr. Susan Love

The influential advocate, surgeon and survivor talks trends, treatment and ways to fast-track breast cancer research

Oct. 9, 2015 | By Diane Mapes / Fred Hutch News Service

Dr. Susan Love

Surgeon, researcher, activist and author Dr. Susan Love worked with Sage Bionetworks, based at Fred Hutch, to develop Share the Journey, an iPhone crowdsourcing app designed to track the side effects of breast cancer treatment.

Photo courtesy of Dr. Susan Love Research Foundation

There’s the grin, the glasses, the signature short curly hair ― and then there’s the book, universally touted as the bible for women with breast cancer.

Instantly recognizable, sometimes controversial, Dr. Susan Love may just be the most famous cancer advocate on the planet. She's the face and the force behind major advances in breast cancer research and treatment, including the use of lumpectomy over mastectomy and the tracking and documenting of the “collateral damage” of surgery, chemotherapy and radiation.

A surgeon, researcher, teacher, activist and author, Love is currently the chief visionary officer of the Dr. Susan Love Research Foundation, a clinical professor of surgery at the University of California, Los Angeles and a founder of the National Breast Cancer Coalition. In 2008, she partnered with the Avon Foundation for Women to launch the Army of Women, a cohort of over 375,000 women ready and willing to participate in research. More recently, she worked with Sage Bionetworks, a nonprofit research organization based at Fred Hutchinson Cancer Research Center and led by Dr. Stephen Friend, an affiliate investigator in the Public Health Sciences Division at Fred Hutch, to develop Share the Journey, an iPhone “crowdsourcing” app designed to help track the physical, mental and emotional after-effects of breast cancer treatment.

Love is also a cancer survivor. In June 2012, she was diagnosed with acute myelogenous leukemia and went through seven weeks of hospitalized chemotherapy followed by a bone marrow transplant (her “baby sister” was her donor). That experience has both informed her research (particularly with regard to treatment’s impact on patients) and further inspired her to not just treat breast cancer but find the cause and eradicate it completely.

In 1990, the surgeon-turned-survivor published the first edition of her groundbreaking book, “Dr. Susan Love’s Breast Book.” This month marks the publication of its sixth edition, a perfect occasion to talk to Love about what’s changed and what hasn’t in the realm of breast cancer research and treatment ― and what she hopes lies ahead.

Continue reading >

Toys to totems: Sacred artifacts keep lost loved ones close

Precious playthings of brain cancer patients inspire artful glass replicas

Oct. 8, 2015 | By Bill Briggs / Fred Hutch News Service

Nikki Austin with her son Matthew's favorite toy. The horse inspired glass art in Matthew's memory.

Photo by Robert Hood / Fred Hutch News Service; Photo of glass art by Duncan Price

After death, the mementos left behind are never enough. And yet they are everything.

The precious possessions of loved ones lost often serve as a final, tangible connection, forever binding the grieving to the departed. They become fiercely guarded keepsakes. Or sacred artifacts placed on display. Or both.  

For Libby Kranz, mother of Jennifer, the connection to her daughter is a sparkly piece of costume jewelry. For Nikki Austin, mother of Matthew, it’s a stuffed horse. For Cammy Singh, mother of Rohan, it’s a Lego flying machine. And all three items – Jennifer’s ring, Matthew’s horse and Rohan’s spaceship – now will inspire fresh hope via art.

On Saturday, blown-glass replicas of these “healing objects” will be unveiled at Fred Hutchinson Cancer Research Center during the annual “Light Up the Night” fundraiser. The event supports Project Violet, which discovers effective, new drugs for cancers and rare diseases.

Artist Shirley Klinghoffer and collaborators at the Museum of Glass in Tacoma painstakingly crafted the pieces.

All three of those children died from brain tumors. Two of the kids – Matthew, 11, and Rohan, 7 – were treated by Dr. Jim Olson’s team. Jennifer, 6, was treated near her home in California.

"The words, ‘pediatric cancer’ make most people raise an emotional wall. So how do we engage the public in this very important problem? Through art,” Olson said. “These gorgeous pieces of Shirley Klinghoffer’s create an opportunity for people to get close to our community in a safe and beautiful way."

Klinghoffer, a contemporary artist whose work often deals with themes of vulnerability and strength, added: “It represents a way to show how something that may start out with an unwanted reality can then bring solace. And [how it can] can bring some kind of a relief to the families to let them know that their children’s stories live on.”

Continue reading >

Good News at Fred Hutch

Celebrating faculty and staff achievements

Oct. 8, 2015 | By Fred Hutch staff

Dr. Garnet Anderson

Dr. Garnet Anderson

Photo by Stefanie Felix for Fred Hutch

Public Health Sciences Director Dr. Garnet Anderson among 2015 Puget Sound Business Journal Women of Influence

Puget Sound Business Journal has named Dr. Garnet Anderson, senior vice president and director of the Public Health Sciences Division at Fred Hutchinson Cancer Research Center, among its 2015 Women of Influence. She is among 15 honorees who will receive recognition at an award ceremony at the Hyatt Regency in Bellevue on Nov. 18.

The Women of Influence Awards, now in its 12th year, shines a spotlight on local businesswomen, community leaders and philanthropists who, according to the business journal, are a force in the region and “have the power and authority to move the needle” in their field.

Click here to view the list of this year’s honorees and here for more about the award ceremony.

Anderson’s work has had a significant impact on the lives of hundreds of thousands of women worldwide.

She co-led the nationwide Women’s Health Initiative study that in 2002 found that combined hormone-replacement therapy, or HRT, for menopausal symptoms was not the fountain of youth it was touted to be. While it helped women combat hot flashes, bone loss and other menopause symptoms, it did so at a cost. The study found HRT also significantly raised a woman’s chances of developing cardiovascular disease, stroke and breast cancer.

The landmark findings by Anderson and colleagues triggered a 50 percent decline in the use of HRT, which has resulted in 15,000 to 20,000 fewer cases of breast cancer each year in the U.S. Worldwide, the decreased use of HRT has resulted in additional reductions in breast cancer incidence by tens of thousands of cases per year.

The study also has had a significant economic impact; while the federally funded clinical trial cost $260 million (in 2012 dollars), the net economic return was more than $37 billion. That’s a return of approximately $140 on every dollar invested in the trial, according to an analysis by Anderson and her health economist colleagues in the Hutchinson Institute for Cancer Outcomes Research that was published in the Annals of Internal Medicine.

More important, the findings sparked a sea change in women’s health. Anderson and colleagues estimate that in the decade following the trial, approximately 4.3 million women have stopped taking HRT, resulting in 126,000 fewer breast cancer cases, 76,000 fewer cases of cardiovascular disease and 80,000 fewer cases of venous thromboembolism (potentially deadly blood clots).

In addition to women’s health, Anderson’s research interests and areas of expertise include the design, analysis and conduct of randomized clinical trials, considered the “gold standard” of biomedical research, biostatistics, prevention of chronic disease, and ovarian cancer screening and risk.

Anderson has been on the Public Health Sciences Division faculty since 1989 and has served as its director since 2013. She also is an affiliate professor in the Department of Biostatistics at the University of Washington School of Public Health.

Other Fred Hutch faculty and staff named Women of Influence include Dr. Julie McElrath, senior vice president and director of the Vaccine and Infectious Disease Division (2013) and Myra Tanita, chief operating officer (2011).

Dr. Paul Martin

Dr. Paul Martin

Fred Hutch file

Dr. Paul Martin appointed AACI-CRI Steering Committee chair

Dr. Paul Martin of the Fred Hutch Clinical Research Division has been appointed the new chair of the Association of American Cancer Institutes Clinical Research Initiative Steering Committee.

AACI's CRI provides a forum for clinical research leaders to share information and to advocate for improving the national clinical trials enterprise. CRI objectives include developing better methods to disseminate information across cancer centers, identifying clinical research challenges, and sharing proven means of addressing challenges and measuring progress. The CRI program aligns with AACI's strategic goal to stimulate interactions among cancer centers in order to maximize the use of resources and to facilitate research. The individuals involved in CRI fill a variety of leadership roles and possess a comprehensive understanding of their center's entire clinical trials system.

Martin is medical director of Clinical Research Support at Fred Hutch. He has served on the AACI-CRI Steering Committee since November 2013, and his two-year term as chair began Sept. 1.

Seattle Mayor Ed Murray: A candid chat on guns, homelessness and diversity

A wide-ranging Q&A session at Fred Hutch spans mayor's views and values

Oct. 7, 2015 | By Sabin Russell / Fred Hutch News Service

Seattle Mayor Ed Murray addresses a packed house in the Pelton Auditorium on the Fred Hutch campus on Oct. 7, 2015. He spoke to the Hutch Diversity Council forum about politics, leadership and LGBT issues.

Photo by Robert Hood / Fred Hutch News Service

Seattle Mayor Ed Murray, during a visit to the city’s Fred Hutchinson Cancer Research Center, said gun violence and homelessness are the two most intractable issues facing him today. To tackle them successfully requires a shift in culture ― easier said than done and, most often, not done at all.

He pointed to public-health approaches to homelessness and drug abuse as the most viable remedy for these deeply rooted social problems. That would mean, for instance, coming to grips with a heroin epidemic in the Northwest “the likes of which we haven’t seen since the '60s.” Yet he noted that social service programs to curb illegal drug use and address mental health are starved for funds.

Gun violence, too, he likened to an epidemic with no politically palatable treatment in sight. “There is bipartisan support to do nothing to change our gun laws,” said the mayor, an active proponent of gun control measures that have gained no traction.“When the culture changes, the politics change,” he said, but on matters involving gun violence, “we’re pretty stuck.”

Murray said he continues to look for ways to reduce the availability of high-powered weaponry. “I grew up hunting. My uncles had guns. But they were hunting rifles, not semiautomatics.” While he sees no prospects for gun control legislation, he said the city is looking to leverage its potential clout with gun-makers as a buyer of ammunition for local law enforcement. That strategy is being tried in Jersey City, New Jersey. 

Murray was invited to speak to research center staff in Pelton Auditorium by the Hutch Diversity Council, an organization that promotes diversity in hiring and holds frequent seminars on related issues within the region.

“Diversity is intentional,” the mayor said, noting that while liberal Seattle generally respects diversity in principle, implementing wholesale change toward a more-diverse workforce is another matter. 

Murray, while discussing his cabinet, said that may have meant letting white, male city appointees go, and hiring women, racial and ethnic minorities, gays and lesbians. “This is the most conservative liberal city in America. We want diversity, but we don’t want to change anything,” he said.

Continue reading >

Scratching the surface of a rare skin cancer

Immune-boosting therapy shows promise for advanced Merkel cell carcinoma

Oct. 6, 2015 | By Dr. Rachel Tompa / Fred Hutch News Service

Drs. Paul Nghiem and Erica Shantha

Skin cancer researchers Drs. Paul Nghiem and Erica Shantha discuss a sample of a rare skin cancer, Merkel cell carcinoma. Nghiem leads a clinical trial for patients with advanced stages of the disease that is showing promising early results.

Photo by Robert Hood / Fred Hutch News Service

Dr. Paul Nghiem originally had no interest in specializing in an extremely rare cancer.

In 2000, when Nghiem was a newly-minted dermatology resident working in Boston, he had seen exactly one patient with the skin cancer, known as Merkel cell carcinoma. But the disease was (and is) so uncommon — afflicting only 1,500 people per year in the U.S. — that Nghiem’s senior professor talked him into writing a textbook chapter on the cancer based on that sole patient encounter.

A resident who’d seen one patient “was somebody who knew a lot about it, compared to most [doctors],” said Nghiem. “I’m obviously making a joke, because I knew virtually nothing.”

In the 15 years since, Nghiem has thrown himself into everything Merkel cell, developing a career as a skin cancer researcher at the University of Washington (where he recently became head of the dermatology department) and Fred Hutchinson Cancer Research Center, as well as seeing patients with skin cancers at Seattle Cancer Care Alliance. Now, his clinical and research team’s efforts are starting to pay off.

At the European Cancer Congress held in late September in Vienna, Nghiem presented promising, early results from a clinical trial he leads based at seven sites around the U.S. testing an immunotherapy drug known as pembrolizumab (brand-name Keytruda) for patients with advanced Merkel cell carcinoma.

Continue reading >


Support our quest for cures

For the Media

News releases >
Media coverage >
Contact us >

Story Archive


Hutch Magazine
Our quarterly magazine

Annual Report
Fiscal year highlights

Science Spotlight
Monthly review of Center-authored papers

Fred Hutch News

Get updates via email.